A Comprehensive Regional Neurochemical Theory in Depression: a Protocol for the Systematic Review and Meta-analysis of 1H-MRS Studies in Major Depressive Disorder

Overview

Journal Syst Rev

Publisher Biomed Central

Date 2018 Oct 13

PMID 30309391

Citations 6

Authors

Thomas Drago

Patrick W ORegan

Ivan Welaratne

Shane Rooney

Aoife OCallaghan

Marissa Malkit

Elena Roman

Kirk J Levins

Lauren Alexander

Denis Barry

Erik OHanlon

Veronica OKeane

Darren William Roddy

Affiliations

Soon will be listed here.

Abstract

Background: Magnetic resonance spectroscopy (MRS) is a non-invasive analytical technique that investigates the presence and concentrations of brain metabolites. In the context of major depressive disorder (MDD), MRS has revealed regional biochemical changes in GABA, glutamate, and choline across different brain compartments. Technical and methodological advances in MRS data acquisition, in particular proton-based H-MRS, have resulted in a significant increase in the incidence of reports utilizing the technique for psychiatric disorder research and diagnosis. The most recent comprehensive meta-analysis reviewing MRS in MDD stems from 2006. Using contemporary systemic reviews and meta-analysis, the aim is to first test a neurochemical circuit-based theory of depression and then to determine if clinical scores relate to metabolite concentrations before and during treatment.

Methods: Region-specific metabolite changes in MDD will be assessed by systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Inclusion criteria will include participant age (18 to 65), English language studies, known regions of interest, and detailed documentation of H-MRS procedures. Reported brain regions will be standardized according neuroanatomical expertise allowing increased power of the meta-analysis. Regions of interest will initially include the hippocampus, thalamus, prefrontal cortex, anterior and posterior cingulate gyri, parietal lobe, and basal ganglia. Exclusion criteria will include comorbid psychiatric illness and drug use. Two independent reviewers will undertake all data extraction, while a third reviewer will check for reviewer discrepancies. Statistical analysis will be performed using STATA supplemented by Metan software and SPSS.

Discussion: This data will shed new light on the biochemical basis of depression in different brain regions, thereby highlighting the potential of MRS in identifying biomarkers and generating models of MDD and treatment response.

Systematic Review Registration: PROSPERO CRD42018091494.

Citing Articles

Investigating the effectiveness of oral ketamine on pain, mood and quality of life in treatment resistant chronic pain.

Al Mukhaizeem S, Nasa A, Waldron D, McDaid A, Gorman P, Featherstone M Front Pain Res (Lausanne). 2023; 4:1268985.

PMID: 38077652 PMC: 10702242. DOI: 10.3389/fpain.2023.1268985.

Childhood Trauma, the HPA Axis and Psychiatric Illnesses: A Targeted Literature Synthesis.

Murphy F, Nasa A, Cullinane D, Raajakesary K, Gazzaz A, Sooknarine V Front Psychiatry. 2022; 13:748372.

PMID: 35599780 PMC: 9120425. DOI: 10.3389/fpsyt.2022.748372.

MRI volumetric changes in hippocampal subfields in psychosis: a protocol for a systematic review and meta-analysis.

Nasa A, Mosley O, Roman E, Kelliher A, Gaughan C, Levins K Syst Rev. 2022; 11(1):44.

PMID: 35292116 PMC: 8925181. DOI: 10.1186/s13643-022-01916-5.

Magnetic resonance spectroscopy across chronic pain disorders: a systematic review protocol synthesising anatomical and metabolite findings in chronic pain patients.

Levins K, Drago T, Roman E, Martin A, King R, Murphy P Syst Rev. 2019; 8(1):338.

PMID: 31882014 PMC: 6935150. DOI: 10.1186/s13643-019-1256-5.

Study protocol for a parallel-group, double-blinded, randomized, controlled, noninferiority trial: the effect and safety of hybrid electroconvulsive therapy (Hybrid-ECT) compared with routine electroconvulsive therapy in patients with depression.

Rong H, Xu S, Zeng J, Yang Y, Zhao J, Lai W BMC Psychiatry. 2019; 19(1):344.

PMID: 31694611 PMC: 6836661. DOI: 10.1186/s12888-019-2320-3.

References

Birur B, Kraguljac N, Shelton R, Lahti A . Brain structure, function, and neurochemistry in schizophrenia and bipolar disorder-a systematic review of the magnetic resonance neuroimaging literature. NPJ Schizophr. 2017; 3:15. PMC: 5441538. DOI: 10.1038/s41537-017-0013-9. View

Dubin M, Mao X, Banerjee S, Goodman Z, Lapidus K, Kang G . Elevated prefrontal cortex GABA in patients with major depressive disorder after TMS treatment measured with proton magnetic resonance spectroscopy. J Psychiatry Neurosci. 2016; 41(3):E37-45. PMC: 4853214. DOI: 10.1503/jpn.150223. View

Zhang Y, Han Y, Wang Y, Zhang Y, Li L, Jin E . A MRS study of metabolic alterations in the frontal white matter of major depressive disorder patients with the treatment of SSRIs. BMC Psychiatry. 2015; 15:99. PMC: 4458012. DOI: 10.1186/s12888-015-0489-7. View

Luscher B, Shen Q, Sahir N . The GABAergic deficit hypothesis of major depressive disorder. Mol Psychiatry. 2010; 16(4):383-406. PMC: 3412149. DOI: 10.1038/mp.2010.120. View

Atagun M, Sikoglu E, Can S, Karakas Ugurlu G, Ulusoy Kaymak S, Caykoylu A . Neurochemical differences between bipolar disorder type I and II in superior temporal cortices: A proton magnetic resonance spectroscopy study. J Affect Disord. 2018; 235:15-19. PMC: 5951770. DOI: 10.1016/j.jad.2018.04.010. View

Drysdale A, Grosenick L, Downar J, Dunlop K, Mansouri F, Meng Y . Resting-state connectivity biomarkers define neurophysiological subtypes of depression. Nat Med. 2016; 23(1):28-38. PMC: 5624035. DOI: 10.1038/nm.4246. View

Coppen A . The biochemistry of affective disorders. Br J Psychiatry. 1967; 113(504):1237-64. DOI: 10.1192/bjp.113.504.1237. View

Easterbrook P, Berlin J, Gopalan R, Matthews D . Publication bias in clinical research. Lancet. 1991; 337(8746):867-72. DOI: 10.1016/0140-6736(91)90201-y. View

Tozzi L, Doolin K, Farrel C, Joseph S, OKeane V, Frodl T . Functional magnetic resonance imaging correlates of emotion recognition and voluntary attentional regulation in depression: A generalized psycho-physiological interaction study. J Affect Disord. 2016; 208:535-544. DOI: 10.1016/j.jad.2016.10.029. View

10.

DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. DOI: 10.1016/0197-2456(86)90046-2. View

11.

Narayana P . Magnetic resonance spectroscopy in the monitoring of multiple sclerosis. J Neuroimaging. 2005; 15(4 Suppl):46S-57S. PMC: 1351238. DOI: 10.1177/1051228405284200. View

12.

Tkac I, Andersen P, Adriany G, Merkle H, Ugurbil K, Gruetter R . In vivo 1H NMR spectroscopy of the human brain at 7 T. Magn Reson Med. 2001; 46(3):451-6. DOI: 10.1002/mrm.1213. View

13.

Maril N, Collins C, Greenman R, Lenkinski R . Strategies for shimming the breast. Magn Reson Med. 2005; 54(5):1139-45. DOI: 10.1002/mrm.20679. View

14.

Salvadore G, van der Veen J, Zhang Y, Marenco S, Machado-Vieira R, Baumann J . An investigation of amino-acid neurotransmitters as potential predictors of clinical improvement to ketamine in depression. Int J Neuropsychopharmacol. 2011; 15(8):1063-72. PMC: 3342437. DOI: 10.1017/S1461145711001593. View

15.

. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016; 388(10053):1545-1602. PMC: 5055577. DOI: 10.1016/S0140-6736(16)31678-6. View

16.

Schur R, Draisma L, Wijnen J, Boks M, Koevoets M, Joels M . Brain GABA levels across psychiatric disorders: A systematic literature review and meta-analysis of (1) H-MRS studies. Hum Brain Mapp. 2016; 37(9):3337-52. PMC: 6867515. DOI: 10.1002/hbm.23244. View

17.

Gigante A, Bond D, Lafer B, Lam R, Young L, Yatham L . Brain glutamate levels measured by magnetic resonance spectroscopy in patients with bipolar disorder: a meta-analysis. Bipolar Disord. 2012; 14(5):478-87. DOI: 10.1111/j.1399-5618.2012.01033.x. View

18.

Valentine G, Mason G, Gomez R, Fasula M, Watzl J, Pittman B . The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS. Psychiatry Res. 2011; 191(2):122-7. PMC: 3061550. DOI: 10.1016/j.pscychresns.2010.10.009. View

19.

Yang X, Kirton A, Wilkes T, Pradhan S, Liu I, Jaworska N . Glutamate alterations associated with transcranial magnetic stimulation in youth depression: a case series. J ECT. 2014; 30(3):242-7. DOI: 10.1097/YCT.0000000000000094. View

20.

Yildiz-Yesiloglu A, Ankerst D . Review of 1H magnetic resonance spectroscopy findings in major depressive disorder: a meta-analysis. Psychiatry Res. 2006; 147(1):1-25. DOI: 10.1016/j.pscychresns.2005.12.004. View